Stocks · Coverage Archive

$ZYME

25.12 ▼ 2.48%

Every Regards of Wallstreet article on $ZYME, newest first — 1 story and counting.

Followed tickers pin their next report date and latest coverage to the homepage and the earnings calendar.

  1. 2026-08-16 · 10 min read

    Is Zymeworks (ZYME) a Buy Before the August 25 FDA Decision? A $250 Million Check Is on the Line

    Zymeworks carries none of the launch risk itself, but a $250 million U.S. milestone and up to $1.5 billion more hinge on the FDA's August 25 call on Ziihera in first-line gastric cancer.

New to options? See our plain-English strategy playbook →

The Week-Ahead Brief

Don’t miss next week’s setups. Get the Saturday brief.

Every Saturday: next week’s earnings dates, Fed days and the trades worth watching, from the same desk that writes the week-ahead hub. Free, built for retail investors.

Subscribing means we email you the newsletter and nothing else. No spam, no sharing your address, unsubscribe in one click. See the privacy policy.